Introduction
The UK Renal Registry (UKRR) collects routine biochemical data from clinical information systems in renal centres in England, Wales and Northern Ireland and receives data from Scotland via the Scottish Renal Registry. Annual cross sectional analyses are undertaken on some of these variables to determine centre level performance against national (Renal Association (RA)) clinical performance measures [1] . This enables UK renal centres to compare their own performance against each other and to the UK average performance. Currently the 5th edition of the UK Renal Association clinical practice guidelines is in practice [1] . This edition commenced in a graded manner in 2009 and includes an expanded number of guideline modules compared to previous editions.
Audit measures for kidney disease increasingly include tighter specification limits in conjunction with a growing evidence base. Out of range observations (e.g. hyperphosphataemia and hypophosphataemia) need to be interpreted cautiously as they may relate to different clinical problems or population characteristics. These will therefore require different strategies to improve centre performance of clinical audit measures. Summary statistical data have been provided to enhance understanding of the population characteristics of each centre and longitudinal analyses to demonstrate changes over time.
Data are also available on the UKRR data portal at www.renalreg.org. Table 9 .1 lists the recommended biochemical based audit measures from the RA which are relevant to the dialysis population. Several of the audit measures are not currently reported by the UKRR in its annual report; the reasons behind this are varied, but predominantly relate to a high proportion of incomplete data or that the relevant variable is not currently within the specified UKRR dataset. Over time it is hoped to work with the renal community to improve reporting across the range of recommended standards.
Methods
The analyses presented in this chapter relate to biochemical variables in the prevalent dialysis cohort in the UK. The cohort studied were patients prevalent on dialysis treatment on 31st December 2014. Patients receiving dialysis for less than 90 days and those who had changed modality or renal centre in the last 90 days were excluded. Haemodialysis (HD) and peritoneal dialysis (PD) cohorts were analysed separately. A full definition of the cohort including inclusion and exclusion criteria is available in appendix B (www.renalreg.org).
The biochemical variables analysed in this chapter were serum phosphate, calcium (adjusted for albumin), parathyroid hormone and bicarbonate. The method of data collection and validation by the UKRR has been previously described [2] . In brief, for each quarter of 2014 the UKRR extracted biochemical data electronically from clinical information systems in renal centres in England, Wales and Northern Ireland (E,W&NI). Scottish centres have only been included in analyses relating to corrected calcium and phosphate control, with data for their prevalent dialysis cohort being supplied directly by the Scottish Renal Registry. The UKRR does not currently collect data regarding different assay methods mainly because a single dialysis centre may process samples in several different laboratories. The audit measure used for serum phosphate was 1.1-1.7 mmol/L in both the HD and PD cohorts [1, 3] . For centres providing adjusted calcium values, these data were analysed directly as it is these values on which clinical decisions within centres are based. For centres providing unadjusted calcium values, a formula in widespread use was used to calculate adjusted calcium [4] . The audit measure for adjusted calcium depends on the local reference range [3] . For the purposes of these analyses, the UKRR has used the RA guideline standard of adjusted calcium between 2.2-2.5 mmol/L as the audit measure [3] . There are also a variety of methods and reference ranges in use to measure parathyroid hormone (PTH). To enable some form of comparative audit the UKRR has used 2-9 times the median upper limit of the reference range (8 pmol/L) as the audit measure in line with the 5th edition of the RA clinical practice guidelines and KDIGO 2009 guidance [3, 5] . This equates to a PTH range of 16-72 pmol/L. The audit measure used for serum bicarbonate in the HD cohort was 18-24 mmol/L as per the updated haemodialysis guidelines and in the PD cohort was 22-30 mmol/L. A summary of the current RA audit measures for these variables and conversion factors to SI units are given in table 9.2.
Quarterly values were extracted from the database for the last two quarters for calcium, phosphate and bicarbonate and the last three quarters for PTH. Patients who did not have these data were excluded from the analyses. Data completeness was analysed at centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from plots and tables showing centre level performance. Data were also excluded from plots and tables when there were less than 10 patients with data, both at centre or country level. These data were analysed to calculate summary descriptive statistics (maximum, minimum, means with the corresponding standard deviation, medians and interquartile ranges). Where applicable, the percentage achieving the Renal Association standard or other surrogate clinical performance measure was also calculated.
The simultaneous control of all three components of bone and mineral disorder (BMD) parameters were analysed in combination. The proportion of patients with control of none, one, two or three parameters are presented. For the purpose of these analyses a corrected calcium between 2.2-2.5 mmol/L, a phosphate level being maintained at or below 1.7 mmol/L and a PTH level being at or below 72 pmol/L, were evaluated in combination.
Centres report several biochemical variables with different levels of accuracy, leading to problems in comparative evaluation. Normal range (ideally ,2.5 mmol/L) mg/dl = mmol/L × 4
Parathyroid hormone 2-9 times upper limit of normal ng/L = pmol/L × 9.5
Bicarbonate HD patients: 18-24 mmol/L mg/dl = mmol/L × 6.1 PD patients: 22-30 mmol/L For example, in the case of serum bicarbonate, data can be submitted as integer values but some centres submit data to one decimal place. All data has been rounded in an attempt to make all centres more comparable. The number preceding the centre name in each figure indicates the percentage of missing data for that centre. Funnel plot analyses were used to identify outlying centres [6] . The percentage within range for each standard was plotted against centre size along with the upper and lower 95% and 99.9% limits. Centres can be identified on these plots by looking up the number of patients treated in each centre in the relevant table and finding this value on the x-axis. Longitudinal analyses were performed for some data to calculate overall changes in achievement of a performance measure annually from 2004 to 2014 and were recalculated for each previous year using the rounding procedure.
All data are presented unadjusted for case-mix.
Results

Mineral and bone variables Phosphate
In 2014 the following Renal Association clinical practice guideline regarding phosphate management was applicable:
Guideline 3.2 CKD-MBD: Serum phosphate in dialysis patients ' We suggest that serum phosphate in dialysis patients, measured before a ''short-gap'' dialysis session in haemodialysis patients, should be maintained between 1.1 and 1.7 mmol/L (2C)' [3] Overall, 21,732 HD and 3,068 PD patient details from the UK were used to perform serum phosphate analyses in 2014. The data completeness for serum phosphate across the UK was 97.2% for HD and 97.6% for PD patients, although there was considerable variation between centres (tables 9.3, 9.5).
Data completeness for serum phosphate has improved over the last decade in HD patients from 73.2% to 97.2% and in PD patients from 90.0% to 97.6%.
HD centre returns were only low (,90%) for three centres, with the most notable being Sunderland at 0%. With PD patients, five centres had data returns less than 90%. Sunderland PD patients' phosphate returns were 100% complete. The individual centre means and standard deviations are shown in tables 9.3 and 9.5 for HD and PD patients respectively.
For HD 57.5% and for PD 62.7% of patients achieved a phosphate level within the target range specified by the RA clinical audit measure (tables 9.4, 9.6).
The proportion of HD patients with hyperphosphataemia was 29.0% and with hypophosphataemia was 13.5% (table 9.4).
The proportion of PD patients with hyperphosphataemia was 30.3% and with hypophosphataemia was 7.1% (table 9.6, figures 9.3, 9.4).
There was inter-centre and inter-modality variation in the proportion of patients below, within and above the phosphate range specified by the clinical performance measure (figures 9.1-9.4, tables 9.4, 9.6).
Longitudinal analysis demonstrated a small but continued improvement overall against the clinical performance measure in all the countries and modalities (figure 9.5).
Adjusted calcium
In 2014, the following Renal Association clinical practice guideline regarding calcium management was applicable:
Guideline 2.2 CKD-MBD: Serum calcium in dialysis patients (stage 5D) ' We suggest that serum calcium, adjusted for albumin concentration, should be maintained within the normal reference range for the laboratory used, measured before a ''short-gap'' dialysis session in haemodialysis patients. Ideally, adjusted serum calcium should be maintained between 2.2 and 2.5 mmol/L, with avoidance of hypercalcaemic episodes (2D)' [3] . Nicholas/Evans/Shaw/Dawnay In 2014, 21,685 HD and 3,078 PD patients' data from the UK were available for serum adjusted calcium analysis. The data were 97.0% complete for HD patients and 97.9% complete for PD patients overall, although there was between centre variation (tables 9.7, 9.9). From 2004 to 2014 across UK centres, data completeness for serum adjusted calcium increased from 57.2% to 97.0% in HD patients and from 56.8% to 97.9% in PD patients.
Coventry, Dorset, London West, Sunderland and Belfast failed to return locally adjusted calcium results and hence their data are shown using a generic formula that may not be applicable to the calcium and albumin methods used locally and may have over-or underestimated the adjusted calcium. These centres are served by laboratories that report adjusted calcium results and these should be reported to the UKRR.
Of HD patients, 79.1% (95% CI 78.6-79.7%) and of PD patients 79.7% (95% CI 78.2-81.1%) had an adjusted calcium between 2.2-2.5 mmol/L (tables 9.8, 9.10).
The proportion of hypocalcaemic patients in the UK was 10.4% for HD and 7.7% for PD (tables 9.8, 9.10).
The proportion of hypercalcaemic patients in the UK was 10.5% for HD and 12.6% for PD (Tables 9.8, 9.10).
Figures 9.6 and 9.8 present the individual centre level data of achieving serum adjusted calcium levels between 2.2 and 2.5 mmol/L in HD and PD patients respectively. Figure 9 .7 presents the funnel plot of HD patients attaining adjusted calcium levels between 2.2 and 2.5 mmol/L in 2014. Six centres achieved significantly lower results: Edinburgh, Middlesbrough, Birmingham Heartlands, Birmingham QEH, London Barts and London West. However, the London West data may be misleading since the centre failed to return locally adjusted calcium results. Colchester, Reading, Exeter, Stevenage and Glasgow all achieved a significantly higher percentage than the national average. Figure 9 .9 presents the funnel plots of PD patients attaining the adjusted calcium levels between 2.2 and 2.5 mmol/L in 2014. Once corrected for centre size, no centre was significantly lower than the national average. There were two centres achieving a significantly higher percentage compared with the UK average: Dorset and Nicholas/Evans/Shaw/Dawnay London Guys. However, the Dorset data may be misleading since the centre failed to return locally adjusted calcium results.
Longitudinal changes in the control measures of serum adjusted calcium show improvements in the attained national standards. Hypocalcaemia in HD patients has declined since 2010, with no significant changes being observed in PD patients. In the same time period there has been little change in hypercalcaemia in either modality (figure 9.10).
Parathyroid hormone
At the beginning of 2014 the following RA guideline for PTH applied:
Guideline 4.2.1 CKD-MBD: Target range of serum PTH in patients on dialysis ' We suggest that the target range for parathyroid hormone measured using an intact PTH assay should be between 2 and 9 times the upper limit of normal for the assay used (2C)' [3] .
PTH results from 19,354 HD patients and 2,714 PD patients from England, Northern Ireland and Wales were available for analysis from 2014. The data were 93.8% complete for HD patients and 91.7% for PD patients overall, although there was between centre variation (tables 9.11, 9.13). Of HD patients, 57.4% (95% CI 56.7-58.1%) and of PD patients, 65.0% (95% CI 63.1-66.7%) achieved a PTH between 16-72 pmol/L (tables 9.12, 9.14, figures 9.11-9.14).
In 2014, the proportion of HD patients with a PTH above the upper limit of the range (.72 pmol/L) was 16.4% and the proportion below the lower limit of the range (,16 pmol/L) was 26.2%.
The proportion of PD patients with PTH above the upper limit (.72 pmol/L) of the range was 12.0% and the proportion below the lower limit of the range (,16 pmol/L) was 23.1% (tables 9.12, 9.14).
There was significant variation by centre following unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measures. The funnel plot (figure 9.12) for HD patients showed above average achievement of the target range in Antrim, Doncaster, Derby, Kent, Stevenage and London Barts and below average achievement for Liverpool Aintree, Exeter, Leicester and London West. For PD patients (figure 9.14) there were no outliers.
Longitudinal analysis of PTH control measures at the level of the three countries noted sustained reduction in the proportion of patients with low PTH levels (,16 pmol/L) in HD and PD patients. Similarly, there has been a corresponding increase in the fraction of HD and PD patients with PTH levels being maintained within the 16- Nicholas/Evans/Shaw/Dawnay Nicholas/Evans/Shaw/Dawnay patients; and of all three parameters in 50.3% of HD and 52.5% of PD patients (tables 9.15, 9.16).
Figures 9.18 and 9.19 are funnel plots of all centres who contributed data to these analyses based on the size of the centre and the percentage of patients achieving the control of all three BMD parameters. In HD patients, there was a negative trend observed between centre size and the simultaneous control of all three BMD parameters as identified in this analysis.
No such trend was observed in PD patients.
Bicarbonate
In 2014 the following Renal Association clinical practice guidelines regarding bicarbonate management were applicable:
Haemodialysis Guideline 6.3: Pre-dialysis serum bicarbonate concentrations 'We suggest that pre-dialysis serum bicarbonate concentrations, measured with minimum delay after venepuncture, should be between 18 and 24 mmol/L' [7] .
Peritoneal Dialysis Guideline 6.2 -PD: Metabolic factors ' We recommend that plasma bicarbonate should be maintained within the normal range' [8] .
A total of 18,671 HD and 2,603 PD patients' data were available for serum bicarbonate analysis from England, Wales and Northern Ireland in 2014. Data were 90.5% Nicholas/Evans/Shaw/Dawnay As in previous reports, inter-centre variation was observed in attainment of the audit standard for both HD and PD groups (tables 9.18, 9.20, figures 9.20-9.23). The funnel plot of serum bicarbonate values in 2014 for HD patients (figure 9.21) showed a large dispersal of attainment, 19 centres being above average and 20 below average. In contrast the funnel plot for PD patients (figure 9.23) showed few outliers. Sample processing, case-mix, differences in dialysis, residual renal function and oral bicarbonate prescriptions may all contribute to the variation observed.
Serial trends in serum bicarbonate measures between 2004 and 2014 by dialysis modality are presented in figure 9 .24. Achievement of bicarbonate audit measures has not changed over the past decade for either modality. Nicholas/Evans/Shaw/Dawnay Nicholas/Evans/Shaw/Dawnay There has been a consistent difference between the modalities in the percentage with raised bicarbonate measures.
Conclusions
In summary, serum bicarbonate levels have not changed significantly, but it was observed that a persistent fraction of HD patients remained with raised bicarbonate levels. The UKRR has previously conducted a limited survey [9] into the possible underlying causes of serum bicarbonate variation. The study examined measures of sample processing and of dialysis treatment. It did not adjust for case-mix and was unable to detect any significant differences between centres. Studies have identified an increased risk of death stratified by a reduced pre dialysis serum bicarbonate level (,17 mmol/L) or with raised levels (.27 mmol/L) [10] [11] [12] [13] , as well as with raised dialysate bicarbonate concentrates [13] . Future analysis of management of acidosis will have to re-explore the factors associated with an increased trend in developing alkalosis in HD patients.
Analyses within this chapter present the ongoing improvement in achieving measures of bone and mineral disease management (BMD) in ESRF patients in the UK. In order to optimise BMD control further, it is necessary to explore confounding factors and applying adjustments to a number of case mix factors. These considerations can only be applied once the UKRR has access to an enhanced dataset from each centre. Many centres are updating their own IT systems, with an ambition that all new developments will comply with the National Renal Dataset. Thus, in future analyses, it may be possible to integrate details of assays used for the biochemical parameters, the local reference ranges adhered to, the dialysis dose and dialysate concentrations prescribed, as well as accessing all details of phosphate binder, calcium mimetic and vitamin D analogue use.
A number of studies have demonstrated reduced patient survival with disordered calcium and phosphate levels in dialysis patients [14] [15] as well as with inadequate simultaneous control of three BMD parameters [13, 16, 17] .
The UKRR 17th Annual Report chapter 8 [18] discussed the problems related to variations in calcium and PTH measurements. The inter and intra centre variation in the control of BMD parameters remains a challenge. So far, it has not been possible to perform analyses to examine these variations as the UKRR is faced with confounding factors, such as the completeness of data returns, as well as the differing assays used for PTH and albumin estimation.
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